The earnings call presents a predominantly positive outlook with a strong performance of Attruby, significant revenue growth, and promising pipeline advancements. However, increased operating expenses and competitive pressures are noted challenges.

Company Guidance -

Q3 2025

During the second quarter of fiscal year 2025, BridgeBio Pharma reported robust financial and operational results, particularly highlighting the performance of their product Attruby. Attruby achieved 100% revenue growth compared to the previous quarter, generating $78 million in global sales and $71.5 million in U.S. net sales. The number of unique patient prescriptions for Attruby reached 3,751, with 1,074 unique prescribers, and the company observed over 30% growth in weekly scripts. Attruby's launch was marked by a significant uptick in treatment-naive patients, contributing to an increase in new patient starts to around 120 per week. BridgeBio also announced progress in their late-stage pipeline, anticipating results from three key Phase III trials in ADH1, LGMD2I, and achondroplasia in the coming months. The company ended the quarter with a strong cash position of $756.9 million and expressed confidence in their ability to execute future rare disease launches.

Strong Launch of Attruby

Attruby achieved $71.5 million in net product revenue, representing 100% growth over Q1, marking significant progress in the ATTR cardiomyopathy market.

Expansion in ATTR-CM Market

Attruby is capturing significant market share in a rapidly expanding ATTR-CM market, with expectations to reach $15 billion to $20 billion at peak.

Pipeline Advancements

BridgeBio is poised for major advancements with three upcoming Phase III readouts, each representing potential $1 billion+ opportunities.

Positive Financial Performance

Total revenues increased significantly to $110.6 million, driven by the successful launch of Attruby and strategic monetization initiatives.

Improved Access Programs

Attruby's access programs are noted as the most generous in the industry, with nearly 90% of patients paying $0 out-of-pocket.

BridgeBio Pharma (BBIO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

BBIO Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	-0.83 / -	-0.86	―	―	―
Aug 05, 2025	2025 (Q2)	-0.79 / -0.95	-0.39	-143.59% (-0.56)	―
Apr 29, 2025	2025 (Q1)	-0.92 / -0.88	-0.2	-340.00% (-0.68)	―
Feb 20, 2025	2024 (Q4)	-1.12 / -1.40	-0.96	-45.83% (-0.44)	―	―
Nov 12, 2024	2024 (Q3)	-1.00 / -0.86	-1.08	20.37% (+0.22)	―	―
Aug 01, 2024	2024 (Q2)	-1.00 / -0.39	-0.98	60.20% (+0.59)	―	―
May 02, 2024	2024 (Q1)	-0.74 / -0.20	-0.92	78.26% (+0.72)	―	―
Feb 22, 2024	2023 (Q4)	-0.87 / -0.96	-0.92	-4.35% (-0.04)	―	―
Nov 02, 2023	2023 (Q3)	-0.79 / -1.08	-0.93	-16.13% (-0.15)	―	―
Aug 03, 2023	2023 (Q2)	-0.80 / -0.98	-0.07	-1300.00% (-0.91)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

BBIO Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 05, 2025	$49.21	$44.81	-8.94%
Apr 29, 2025	$36.42	$38.36	+5.33%
Feb 20, 2025	$36.29	$36.80	+1.41%
Nov 12, 2024	$26.12	$24.62	-5.74%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does BridgeBio Pharma Inc (BBIO) report earnings?

BridgeBio Pharma Inc (BBIO) is schdueled to report earning on Oct 30, 2025, After Close (Confirmed).

What is BridgeBio Pharma Inc (BBIO) earnings time?

BridgeBio Pharma Inc (BBIO) earnings time is at Oct 30, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is BBIO EPS forecast?

BBIO EPS forecast for the fiscal quarter 2025 (Q3) is -0.84.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing